Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 16/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | DDX6 | P26196 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | CSK | P41240 | 1/20 | 0.57 |
| ▸ | MTOR | P42345 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | PRKDC | P78527 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25360345 | 0.88 | PIK3CA (0.56) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL24714349 | 0.87 | PIK3CA (0.52) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL25415306 | 0.85 | PIK3CA (0.44) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL25358865 | 0.84 | PIK3CA (0.46) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL13759893 | 0.84 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL24714267 | 0.83 | PIK3CB (0.51) | PIK3CBPIK3CAPIK3CDPIK3CG | |
| SCHEMBL3201554 | 0.81 | PIK3CB (0.64) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL30858114 | 0.80 | PIK3CA (0.46) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL31314650 | 0.80 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3CGSRC | |
| SCHEMBL4356462 | 0.80 | PIK3CB (0.68) | PIK3CBPIK3CAPIK3CDPIK3CGSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | claimed |
| CN-118852326-A | PROTAC compound for targeted degradation of PI3K 110 beta and preparation method and application thereof | 河南大学 | 2024-10-29 | — | — | CN | disclosed |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| WO-2022164812-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-7598377-B2 | (+-)-7-Methyl-2-morpholin-4-yl-9-(1-phenylaminoethyl)-pyrido[1,2-a]pyrimidin-4-one, for example; selective inhibitors of phosphoinositide (PI) 3-kinase beta for use in anti-thrombotic therapy | ASTRAZENECA AB (SE) | 2009-10-06 | — | — | US | disclosed |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | PIK3CB 4/4885PIK3CA 11/4885PIK3CD 8/4885 |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | PIK3CB 2/4885PIK3CA 1/4885PIK3CD 4/4885 |
| US-20090191177-A1 | Enantiomerically Pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-A]pyrimidin-9-yl)ethylamino]benzoic Acid, Its Use In Medical Therapy, And A Pharmaceutical Composition Comprising It - 026 | ITK, PI4KA, PIK3CA | PIK3CB 9/4885PIK3CA 3/4885PIK3CD 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.